头部医院纷纷下场之后，二级医院、民营医院、第三方检查检验中心等机构纷纷开始申请数据资产凭证，在当地交易所上架自己的健 康数据资产。 自2024年11月首都医科大学宣武医院完成北京首例健康数据交易后，2025年4月又有福州市长乐区医院向福州数据技术研究院销售100 余例颅脑MRI影像数据，所得收入纳入国库，成为医疗数据资产使用费纳入国库的"全国首单"。 然而，健康数据供应方数量的增加尚未突破质变的临界点，以及对于买方使用数据的安全性没有进一步政策规范，导致供需双方的需 求点暂无匹配，整个健康数据交易市场的生长速度依旧缓慢。 以至于为了拓展更多客户，部分交易所的工作人员会拨通每一个注册者的电话，抓紧每一个促成数据交易成果的可能。 自2023年10月国家数据集成立以来，我国的数据要素已经经历了近两年时间发展，几乎完备了所有职能部门。那么，究竟是什么阻碍 了医疗健康数据交易，乃至整个数据交易市场的发展？ 01 | 序号 | 数据集 | 数据来源 | 数据维度 | 存儲大小 | 参考价格 | 登记时间/上架时间 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 儿童 ...

Core Viewpoint - The stock of Yimai Sunshine (02522) rose over 6% in early trading, reflecting positive market sentiment following the completion of its first data transaction by its subsidiary, Beijing Yimai Information [1] Group 1: Company Developments - Yimai Sunshine completed its first data transaction on September 1, with its CT chest lesion annotation data listed on the Shanghai Data Exchange on August 25 and passing compliance review by the Beijing International Big Data Exchange [1] - The company signed a tripartite cooperation contract with a data technology company and the Beijing International Big Data Exchange, successfully completing the transaction [1] - This collaboration provides a new model for monetizing the company's core data assets and highlights its professional capabilities and market value in the medical imaging data sector [1] Group 2: Financial Activities - The company announced a plan to place 35 million shares, aiming to raise approximately HKD 562 million [1] - About 40% of the raised funds will be allocated to the development of data and artificial intelligence, focusing on enhancing capabilities in medical imaging data mining, annotation, and cleaning, as well as developing an AI application platform [1] - 30% of the funds will be used for continuous expansion of the company's medical imaging center business and enabling solution business through self-investment or acquisitions, targeting both domestic and overseas markets, including Hong Kong and Singapore [1]

Core Viewpoint - The company has successfully launched its first batch of CT chest lesion annotation data on the Shanghai Data Exchange, marking a significant step in the marketization of data assets and showcasing its expertise in medical imaging data [1] Group 1: Data Transaction Details - The data set was officially approved and launched on August 25, 2025, through the Beijing International Big Data Exchange [1] - A tripartite cooperation contract was established between the company's subsidiary, a data technology and application company, and the Beijing International Big Data Exchange [1] - The first data transaction was completed on September 1, 2025, in accordance with the tripartite cooperation contract [1] Group 2: Market Implications - The transaction aims to promote the standardized integration and market-oriented trading of data elements [1] - Conducting the transaction on the North Data Exchange platform ensures the legality and compliance of the trading process, protecting the rights and interests of all parties involved [1] - This collaboration provides a new model for monetizing the company's core data assets and further highlights its professional capabilities and market value in the medical imaging data sector [1]

Core Viewpoint - The company, Yipai Yangguang (2522.HK), is positioned as a leader in the Chinese medical imaging service sector, leveraging AI technology, data assetization, and international collaboration to regain growth momentum, with a target price of HKD 25.61 set by Guosen Securities, indicating strong potential for recovery and expansion [1][3] Group 1: Business Model and Revenue Structure - Yipai Yangguang has established a comprehensive medical imaging ecosystem through three main business segments: imaging center services (79.64% of revenue), imaging solution services (18.09%), and Yipai Cloud services (2.28%), enhancing its resilience and providing diverse growth pathways [1] - The company operates 106 imaging centers across 16 provinces in China, effectively addressing the uneven distribution of medical resources, and plans to add 1,000 partners by 2025 to further increase market penetration [1] Group 2: AI Technology and Data Assetization - Driven by AI technology, the Yipai Cloud platform has significantly improved diagnostic efficiency and accuracy, with the "CT chest lesion annotation data" successfully listed on the Shanghai Data Exchange in April 2025, marking a key step in data assetization [2] - The subsidiary, Yinghe Medical, has developed a medical imaging base model with an accuracy rate exceeding 95%, laying the foundation for a domestic 2.0 era in imaging AI [2] - The company is actively involved in industry standardization, aligning its initiatives with national policies, thereby strengthening its influence in the sector [2] Group 3: International Expansion and Financial Strategy - Yipai Yangguang is accelerating its international expansion by forming the "Yipai Medical Health Technology Alliance" with Meisi Health (2138.HK) to create a global medical technology supply chain platform, with plans to establish model centers in Singapore and Malaysia [2] - The company aims for overseas revenue to account for 30% of total revenue within five years, capitalizing on the cost-effectiveness of Chinese medical services [2] - To support its strategic initiatives, the company recently raised HKD 195 million through a share placement for acquisitions, overseas expansion, and R&D, while also initiating an H-share buyback plan, reflecting management's confidence in long-term value [3]